Novo Nordisk (NYSE: NVO) has been a fantastic, market-beating stock to own for the past decade. Its 10-year return is an incredible 527%, which dwarfs the S&P 500‘s 182% gain during the same period. But it wasn’t until 2022 that the stock really took off. Up until then, its returns were more comparable to that […]
Tag: Novo
Denmark Raises Growth Forecast as Novo Nordisk Expands Output
(Bloomberg) — Denmark’s government now predicts the economy will expand 2.7% this year, almost double the rate it previously estimated, accelerated by the Scandinavian country’s flourishing pharmaceutical company Novo Nordisk A/S. Most Read from Bloomberg The economy ministry raised its 2024 gross domestic product growth forecast from a December estimate of 1.4%. In 2025, GDP […]
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly’s share price more than quadrupling and Novo’s shares more than tripling over the last three years. Meanwhile, Pfizer‘s (NYSE: PFE) fortunes have taken a different path. The big pharma […]
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk (NVO) stock was trading down Thursday despite strong first quarter results, beating Wall Street consensus, led by the blockbuster GLP-1s Ozempic for diabetes and Wegovy for weight loss. Novo posted total sales up 25%, totaling $9.5 billion in revenue from all of its drugs and beating estimates of $9.2 billion. Wegovy brought in […]
Novo Nordisk Stock Dips As Q1 Wegovy Sales Double, But Miss Target
Novo Nordisk (NVO) stock eased a fraction early Thursday after the weight-loss drugs leader reported adjusted income of 81 cents per share on $9.36 billion in first-quarter sales. X On average, analysts surveyed by FactSet expected Novo to earn 75 cents a share on $9.13 billion in sales. Notably, weight-loss drug Wegovy soared 106%, to […]
Novo Nordisk raises outlook fuelled by obesity drug demand
By Maggie Fick LONDON (Reuters) – Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The small raise to the outlook and forecast-beating results underscore Wegovy’s success and […]
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Ozempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that’s what has happened with Novo Nordisk‘s two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big […]
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Eli Lilly and Novo Nordisk are two of the biggest names in healthcare thanks in large part to some promising weight-loss drugs in their respective portfolios. In the past 12 months, Eli Lilly has doubled in value, while Novo Nordisk’s stock is up around 50%. Those who haven’t invested in these stocks may be inclined […]
Eli Lilly, Novo Euphoria Risks Disappointing Investors, Goldman Says
(Bloomberg) — The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S to record peaks is raising the stakes for investors, according to Goldman Sachs Group Inc. analysts. Most Read from Bloomberg “Expectations are high, which heightens the risk to potentially disappoint,” according to analyst Chris Shibutani, who said investors […]
Novo Nordisk’s Stock Could Get Another Boost, Thanks to This Huge Development
Novo Nordisk (NYSE: NVO) has become one of the most valuable healthcare stocks in the world, largely due to a couple of exceptional drugs, Ozempic and Wegovy. While the former is a diabetes drug and the latter is approved for weight loss, consumers have been using both to help lose weight. And their effectiveness has […]
After Wegovy’s Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
Diabetes and obesity care are two engines fueling the pharmaceutical industry right now. Novo Nordisk (NYSE: NVO) is at the forefront of these markets thanks to its red-hot blockbuster drugs Ozempic, Rybelsus, and Wegovy. 2024 has been a milestone year for Novo Nordisk, and the momentum doesn’t appear to be slowing down. Let’s dig into […]
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in the regulation of blood sugar levels and appetite, and they’ve proven their efficacy in clinical trials and the real world. All of […]